Clinical Trial Update: A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） [Phase 2]

View source ↗

Summary

Phase II study evaluating dose optimization of Fruquintinib in elderly colorectal cancer patients refractory to standard treatment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)

Snippet

Sponsor: Zhen-Yu Ding | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED